Results 141 to 150 of about 107,831 (252)

Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy

Alimentary Pharmacology &Therapeutics, EarlyView.
The gut microbiome modulates ulcerative colitis pharmacotherapy through microbial drug metabolism, immune regulation and altered drug bioavailability. Microbial composition influences response to aminosalicylates, corticosteroids, immunomodulators, biologics and small molecules, while microbiome‐targeted therapies show emerging promise.
Kate Collins, Srinivas Kamath, Rachel H. Davis, Samuel P. Costello, Robert V. Bryant, Alice S. Day, Paul Joyce   +6 more
wiley   +1 more source

Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1. [PDF]

JCEM Case Rep
Lim A, Peluso EM, Downs IA, Horwich BH, Velez-Velez MA, Lechner MG.   +5 more
europepmc   +1 more source

Long‐Term Safety and Efficacy of Obeticholic Acid in Patients With Primary Biliary Cholangitis: Final Results of the POISE Long‐Term Safety Extension

Alimentary Pharmacology &Therapeutics, EarlyView.
In the POISE open‐label extension, patients with primary biliary cholangitis with inadequate response or intolerance to ursodeoxycholic acid received long‐term obeticholic acid (OCA) treatment. Findings demonstrated a safety profile consistent with the known characteristics of OCA, with no unexpected safety signals, while supporting sustained efficacy ...
Christopher L. Bowlus, Frederik Nevens, Kris V. Kowdley, Alan Bonder, Thomas Capozza, Jing Li, Radhika Nair, Michael Trauner, David E. Jones   +8 more
wiley   +1 more source

Anti-Ku Antibodies in a Patient With a Polymyositis-Systemic Sclerosis Overlap Syndrome in Association With Autoimmune Hepatitis. [PDF]

Cureus
Zubair M, Wazir M, Ullah F, Thomson SJ, Hepburn A.   +4 more
europepmc   +1 more source

Hepatitis C and autoimmune hepatitis [PDF]

Hepatology, 2000
openaire   +2 more sources

Review article: Immunosuppression in Decompensated Autoimmune Hepatitis Cirrhosis ‐ To Suppress or Not to Suppress?

Alimentary Pharmacology &Therapeutics, EarlyView.
Individualized assessment identifies patients with decompensated autoimmune hepatitis cirrhosis who are likely to benefit from a time‐limited trial of immunosuppression versus those requiring immediate liver transplant evaluation. Early objective response monitoring (bilirubin, MELD‐Na and AST/ALT) guides continuation of immunosuppression, promotes ...
Pedro Robson Costa Passos, Valbert Oliveira Costa Filho, Guilherme Grossi Lopes Cançado   +2 more
wiley   +1 more source

Type 2 Autoimmune Pancreatitis in a Young Adult Male: A Diagnostic Challenge. [PDF]

Cureus
Alavi R, Hussaini S, Gonzalez Velazquez J, Eshaghi F, Patel S.   +4 more
europepmc   +1 more source

Phenotype‐specific immune profiles and outcomes in childhood autoimmune neutropenia: A 20‐year cohort study

British Journal of Haematology, EarlyView.
Summary Childhood autoimmune neutropenia (AIN) encompasses heterogeneous entities; phenotype‐specific immunological profiles and their relationship to infection outcomes remain incompletely defined. To characterise clinical, immunological and long‐term outcomes across distinct phenotypes of childhood AIN.
Ioanna Saougou, Chrysoula Kosmeri, Nikolaos Chaliasos, Irene Mavroudi, Charalampos Pontikoglou, Alexandros Makis   +5 more
wiley   +1 more source

Leukocytoclastic vasculitis associated with <i>Chlamydia pneumoniae</i> respiratory infection: A case report. [PDF]

IDCases
Vora NN, Todorowski H, Paulson M, Bhanot N.   +3 more
europepmc   +1 more source

Serum immunoglobulin G levels in patients with cirrhosis due to autoimmune hepatitis or other etiologies. [PDF]

Eur J Gastroenterol Hepatol
Su Y, Wang Q, Sun X, Zhao X, Zhao X, Jia J, Shan S.   +6 more
europepmc   +1 more source